keyword
MENU ▼
Read by QxMD icon Read
search

Luca Richeldi

keyword
https://www.readbyqxmd.com/read/29018526/design-of-the-pf-ild-trial-a-double-blind-randomised-placebo-controlled-phase-iii-trial-of-nintedanib-in-patients-with-progressive-fibrosing-interstitial-lung-disease
#1
Kevin R Flaherty, Kevin K Brown, Athol U Wells, Emmanuelle Clerisme-Beaty, Harold R Collard, Vincent Cottin, Anand Devaraj, Yoshikazu Inoue, Florence Le Maulf, Luca Richeldi, Hendrik Schmidt, Simon Walsh, William Mezzanotte, Rozsa Schlenker-Herceg
600 patients aged ≥18 years will be randomised in a 1:1 ratio to nintedanib or placebo. Patients with diagnosis of IPF will be excluded. The study population will be enriched with two-thirds having a usual interstitial pneumonia-like pattern on HRCT. The primary endpoint is the annual rate of decline in forced vital capacity over 52 weeks. The main secondary endpoints are the absolute change from baseline in King's Brief Interstitial Lung Disease Questionnaire total score, time to first acute interstitial lung disease exacerbation or death and time to all-cause mortality over 52 weeks...
2017: BMJ Open Respiratory Research
https://www.readbyqxmd.com/read/28993537/long-term-treatment-of-patients-with-idiopathic-pulmonary-fibrosis-with-nintedanib-results-from-the-tomorrow-trial-and-its-open-label-extension
#2
Luca Richeldi, Michael Kreuter, Moisés Selman, Bruno Crestani, Anne-Marie Kirsten, Wim A Wuyts, Zuojun Xu, Katell Bernois, Susanne Stowasser, Manuel Quaresma, Ulrich Costabel
The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week period followed by a further blinded treatment period and an open-label extension. We assessed outcomes across these periods in patients randomised to nintedanib 150 mg twice daily or placebo at the start of TOMORROW. The annual rate of decline in FVC was -125.4 mL/year (95% CI -168.1 to -82.7) in the nintedanib group and -189.7 mL/year (95% CI -229.8 to -149.6) in the comparator group. The adverse event profile of nintedanib remained consistent throughout the studies...
October 9, 2017: Thorax
https://www.readbyqxmd.com/read/28980371/managing-patients-with-interstitial-lung-disease-two-more-pieces-of-the-puzzle
#3
EDITORIAL
Francesco Macagno, Paolo Maria Leone, Luca Richeldi
No abstract text is available yet for this article.
November 2017: Respirology: Official Journal of the Asian Pacific Society of Respirology
https://www.readbyqxmd.com/read/28933616/are-newly-launched-pharmacotherapies-efficacious-in-treating-idiopathic-pulmonary-fibrosis-or-is-there-still-more-work-to-be-done
#4
Riccardo Inchingolo, Carola Condoluci, Andrea Smargiassi, Annelisa Mastrobattista, Cristina Boccabella, Alessia Comes, Nicoletta Golfi, Luca Richeldi
Idiopathic pulmonary fibrosis (IPF) is a challenging and multifactorial disease that has been thought for some time to lack effective treatments. The approval of two drugs, nintedanib and pirfenidone, has heralded a new era in its management. Areas covered: Currently, there is a growing interest on therapeutic strategies. Many studies have been designed and performed, although few of them turned out to be successful. Nowadays, nintedanib and pirfenidone are considered disease modifying drugs, recommended treatments by current evidence-based guidelines...
October 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28889759/nintedanib-with-add-on-pirfenidone-in-idiopathic-pulmonary-fibrosis-results-of-the-injourney-trial
#5
Carlo Vancheri, Michael Kreuter, Luca Richeldi, Christopher J Ryerson, Dominique Valeyre, Jan C Grutters, Sabrina Wiebe, Wibke Stansen, Manuel Quaresma, Susanne Stowasser, Wim A Wuyts
RATIONALE: Nintedanib and pirfenidone slow the progression of IPF, but the disease continues to progress. More data are needed on the safety and efficacy of combination therapy with nintedanib and add-on pirfenidone. OBJECTIVES: To investigate safety, tolerability, pharmacokinetic and exploratory efficacy endpoints in patients treated with nintedanib and add-on pirfenidone versus nintedanib alone. METHODS: Patients with IPF and FVC ≥50% predicted at screening who completed a 4-5 week run-in with nintedanib 150 mg bid without dose reduction or treatment interruption were randomized to nintedanib 150 mg bid with add-on pirfenidone (titrated to 801 mg tid), or nintedanib 150 mg bid alone, open-label for 12 weeks...
September 10, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/28860269/diagnostic-accuracy-of-a-clinical-diagnosis-of-idiopathic-pulmonary-fibrosis-an-international-case-cohort-study
#6
Simon L F Walsh, Toby M Maher, Martin Kolb, Venerino Poletti, Richard Nusser, Luca Richeldi, Carlo Vancheri, Margaret L Wilsher, Katerina M Antoniou, Jüergen Behr, Elisabeth Bendstrup, Kevin Brown, Lucio Calandriello, Tamera J Corte, Vincent Cottin, Bruno Crestani, Kevin Flaherty, Ian Glaspole, Jan Grutters, Yoshikazu Inoue, Maria Kokosi, Yasuhiro Kondoh, Vasileios Kouranos, Michael Kreuter, Kerri Johannson, Eoin Judge, Brett Ley, George Margaritopoulos, Fernando J Martinez, Maria Molina-Molina, António Morais, Hilario Nunes, Ganesh Raghu, Christopher J Ryerson, Moises Selman, Paolo Spagnolo, Hiroyuki Taniguchi, Sara Tomassetti, Dominique Valeyre, Marlies Wijsenbeek, Wim Wuyts, David Hansell, Athol Wells
We conducted an international study of idiopathic pulmonary fibrosis (IPF) diagnosis among a large group of physicians and compared their diagnostic performance to a panel of IPF experts.A total of 1141 respiratory physicians and 34 IPF experts participated. Participants evaluated 60 cases of interstitial lung disease (ILD) without interdisciplinary consultation. Diagnostic agreement was measured using the weighted kappa coefficient (κw). Prognostic discrimination between IPF and other ILDs was used to validate diagnostic accuracy for first-choice diagnoses of IPF and were compared using the C-index...
August 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28841036/do-randomized-clinical-trials-always-provide-certain-results-the-case-of-tralokinumab-in-idiopathic-pulmonary-fibrosis
#7
Mark G Jones, Giacomo Sgalla, Luca Richeldi
No abstract text is available yet for this article.
August 25, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/28777013/investigational-drugs-for-idiopathic-pulmonary-fibrosis
#8
REVIEW
Francesco Varone, Giuliano Montemurro, Francesco Macagno, Mariarosaria Calvello, Emanuele Conte, Enrica Intini, Bruno Iovene, Paolo Maria Leone, Pier-Valerio Mari, Luca Richeldi
IPF is a specific form of chronic fibrosing interstitial pneumonia of unknown cause, characterized by progressive worsening in lung function and an unfavorable prognosis. Current concepts on IPF pathogenesis are based on a dysregulated wound healing response, leading to an over production of extracellular matrix. Based on recent research however, several other mechanisms are now proposed as potential targets for novel therapeutic strategies. Areas covered: This review analyzes the current investigational strategies targeting extracellular matrix deposition, tyrosine-kinase antagonism, immune and autoimmune response, and cell-based therapy...
September 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28732832/current-approaches-to-the-management-of-idiopathic-pulmonary-fibrosis
#9
REVIEW
Ganesh Raghu, Luca Richeldi
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease associated with dyspnoea, cough and impaired quality of life. Currently, the aims of patient care are to improve outcomes for patients by slowing the progression of the disease, extending life, and improving quality of life. A prompt, accurate diagnosis is important to enable patients to receive treatment early in the course of the disease and to be considered for lung transplantation. Two anti-fibrotic drugs, nintedanib and pirfenidone, have been shown to reduce decline in lung function in patients with IPF...
August 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/28666965/individualizing-duration-of-antibiotic-therapy-in-community-acquired-pneumonia
#10
Stefano Aliberti, Julio Ramirez, Fabio Giuliani, Timothy Wiemken, Giovanni Sotgiu, Sara Tedeschi, Manuela Carugati, Vincenzo Valenti, Marco Marchioni, Marco Camera, Roberto Piro, Manuela Del Forno, Giuseppe Milani, Paola Faverio, Luca Richeldi, Martina Deotto, Massimiliano Villani, Antonio Voza, Eleonora Tobaldini, Mauro Bernardi, Andrea Bellone, Matteo Bassetti, Francesco Blasi
International experts suggest tailoring antibiotic duration in community-acquired pneumonia (CAP) according to patients' characteristics. We aimed to assess the effectiveness of an individualized approach to antibiotic duration based on time in which CAP patients reach clinical stability during hospitalization. In a multicenter, non-inferiority, randomized, controlled trial hospitalized adult patients with CAP reaching clinical stability within 5 days after hospitalization were randomized to a standard vs. individualized antibiotic duration...
August 2017: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28664861/antacid-therapy-in-idiopathic-pulmonary-fibrosis-more-questions-than-answers
#11
REVIEW
Kerri A Johannson, Irina Strâmbu, Claudia Ravaglia, Jan C Grutters, Claudia Valenzuela, Nesrin Mogulkoc, Fabrizio Luppi, Luca Richeldi, Athol U Wells, Carlo Vancheri, Michael Kreuter
Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue...
July 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28544857/new-treatment-directions-for-ipf-current-status-of-ongoing-and-upcoming-clinical-trials
#12
Francesco Macagno, Francesco Varone, Paolo Maria Leone, Pier-Valerio Mari, Loredana Panico, Ludovica Berardini, Luca Richeldi
The main objective of this review is to explore the wide and expanding field of new clinical trials in IPF. Recent trials have confirmed the efficacy of the approved drugs pirfenidone and nintedanib; nonetheless, the discovery of new biological pathways has opened new horizons in this field. Areas covered: New strategies against matrix deposition are under study and so is for the role of immunity and autoimmunity. Recent advances in the use of stem cells are opening new possibilities for the recovery of damaged lung tissues...
July 2017: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/28526798/acute-exacerbations-in-the-inpulsis-trials-of-nintedanib-in-idiopathic-pulmonary-fibrosis
#13
Harold R Collard, Luca Richeldi, Dong Soon Kim, Hiroyuki Taniguchi, Inga Tschoepe, Maurizio Luisetti, Jesse Roman, Gregory Tino, Rozsa Schlenker-Herceg, Christoph Hallmann, Roland M du Bois
Time to first investigator-reported acute exacerbation was a key secondary end-point in the INPULSIS trials of nintedanib in patients with idiopathic pulmonary fibrosis (IPF).We used the INPULSIS trial data to investigate risk factors for acute exacerbation of IPF and to explore the impact of nintedanib on risk and outcome of investigator-reported and adjudicated confirmed/suspected acute exacerbations. Mortality following these events and events adjudicated as not acute exacerbations was analysed using the log rank test...
May 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28513440/luca-richeldi-high-hopes-for-rare-lung-diseases
#14
Geoff Watts
No abstract text is available yet for this article.
May 13, 2017: Lancet
https://www.readbyqxmd.com/read/28472808/idiopathic-pulmonary-fibrosis-molecular-endotypes-of-fibrosis-stratifying-existing-and-emerging-therapies
#15
Daniele Magnini, Giuliano Montemurro, Bruno Iovene, Linda Tagliaboschi, Rafael Emanuele Gerardi, Erminia Lo Greco, Teresa Bruni, Alessio Fabbrizzi, Francesco Lombardi, Luca Richeldi
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown causes. Current diagnostic criteria are based on radiological, clinical, and histopathological features but, unfortunately, still many patients remain undiagnosed. Two currently approved therapies, pirfenidone and nintedanib, slow down disease progression but failed to block or revert it. On the other hand, many of the therapeutic agents tested in several clinical trials have not given satisfactory answers, probably due to the pathological heterogeneity of the disease...
2017: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/28467787/the-histone-deacetylase-inhibitor-romidepsin-as-a-potential-treatment-for-pulmonary-fibrosis
#16
Franco Conforti, Elizabeth R Davies, Claire J Calderwood, Thomas H Thatcher, Mark G Jones, David E Smart, Sumeet Mahajan, Aiman Alzetani, Tom Havelock, Toby M Maher, Philip L Molyneaux, Andrew J Thorley, Teresa D Tetley, Jane A Warner, Graham Packham, A Ganesan, Paul J Skipp, Benjamin J Marshall, Luca Richeldi, Patricia J Sime, Katherine M A O'Reilly, Donna E Davies
Idiopathic pulmonary fibrosis (IPF) is a progressive disease that usually affects elderly people. It has a poor prognosis and there are limited therapies. Since epigenetic alterations are associated with IPF, histone deacetylase (HDAC) inhibitors offer a novel therapeutic strategy to address the unmet medical need. This study investigated the potential of romidepsin, an FDA-approved HDAC inhibitor, as an anti-fibrotic treatment and evaluated biomarkers of target engagement that may have utility in future clinical trials...
July 25, 2017: Oncotarget
https://www.readbyqxmd.com/read/28414524/a-standardized-diagnostic-ontology-for-fibrotic-interstitial-lung-disease-an-international-working-group-perspective
#17
Christopher J Ryerson, Tamera J Corte, Joyce S Lee, Luca Richeldi, Simon L F Walsh, Jeffrey L Myers, Juergen Behr, Vincent Cottin, Sonye K Danoff, Kevin R Flaherty, David J Lederer, David A Lynch, Fernando J Martinez, Ganesh Raghu, William D Travis, Zarir Udwadia, Athol U Wells, Harold R Collard
Diagnosing fibrotic interstitial lung disease (ILD) requires multidisciplinary integration of clinical, radiological, and pathological features with assignment of a consensus classification. The current approach lacks a standardized ontology and therefore results in diagnostic heterogeneity. The objectives of this international working group perspective are to describe limitations of the current approach to fibrotic ILD diagnosis and to develop an ontological framework for standardizing the diagnostic classification...
April 17, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/28365056/idiopathic-pulmonary-fibrosis
#18
REVIEW
Luca Richeldi, Harold R Collard, Mark G Jones
Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease. Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is destroyed, which leads to decreased lung compliance, disrupted gas exchange, and ultimately respiratory failure and death. In less than a decade, understanding of the pathogenesis and management of this disease has been transformed, and two disease-modifying therapies have been approved, worldwide. In this Seminar, we summarise the presentation, pathophysiology, diagnosis, and treatment options available for patients with idiopathic pulmonary fibrosis...
May 13, 2017: Lancet
https://www.readbyqxmd.com/read/28294649/interstitial-lung-disease-in-india-keep-searching-and-you-ll-keep-finding
#19
Zarir F Udwadia, Luca Richeldi
No abstract text is available yet for this article.
March 15, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/28052967/official-american-thoracic-society-infectious-diseases-society-of-america-centers-for-disease-control-and-prevention-clinical-practice-guidelines-diagnosis-of-tuberculosis-in-adults-and-children
#20
David M Lewinsohn, Michael K Leonard, Philip A LoBue, David L Cohn, Charles L Daley, Ed Desmond, Joseph Keane, Deborah A Lewinsohn, Ann M Loeffler, Gerald H Mazurek, Richard J O'Brien, Madhukar Pai, Luca Richeldi, Max Salfinger, Thomas M Shinnick, Timothy R Sterling, David M Warshauer, Gail L Woods
BACKGROUND: Individuals infected with Mycobacterium tuberculosis (Mtb) may develop symptoms and signs of disease (tuberculosis disease) or may have no clinical evidence of disease (latent tuberculosis infection [LTBI]). Tuberculosis disease is a leading cause of infectious disease morbidity and mortality worldwide, yet many questions related to its diagnosis remain. METHODS: A task force supported by the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America searched, selected, and synthesized relevant evidence...
January 15, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
keyword
keyword
82606
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"